Turkey of the week: racily-priced health player

Healthcare is one of Paul Hill's preferred sectors, but he is bearish on this provider of test kits for diagnosing patients with diabetes and cholesterol.

This is slightly unusual territory for me because healthcare is one of my preferred sectors going into 2009, due to its high barriers to entry, predictable earnings and attractive valuations. So why am I bearish on Axis-Shield, a provider of test kits for diagnosing patients with diabetes and cholesterol? Well, in a nutshell, the share price simply looks too racy for my more value-based appetite.

Axis-Shield (LSE:ASD), rated as a BUY by Piper Jaffray

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

Paul gained a degree in electrical engineering and went on to qualify as a chartered management accountant. He has extensive corporate finance and investment experience and is a member of the Securities Institute.

Over the past 16 years Paul has held top-level financial management and M&A roles for blue-chip companies such as O2, GKN and Unilever. He is now director of his own capital investment and consultancy firm, PMH Capital Limited.

Paul is an expert at analysing companies in new, fast-growing markets, and is an extremely shrewd stock-picker.